Carregant...

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab(®))

The trifunctional antibody (trAb) catumaxomab is characterized by a unique ability to bind three different cell types: tumor cells; T-cells; and accessory cells. It binds to epithelial cell adhesion molecule (EpCAM) on tumor cells, the CD3 antigen on T-cells, and to type I, IIa, and III Fcγ receptor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autor principal: Seimetz, Diane
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3119393/
https://ncbi.nlm.nih.gov/pubmed/21716847
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!